Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Namir J Hassan"'
Autor:
Jane Harper, Katherine J Adams, Giovanna Bossi, Debbie E Wright, Andrea R Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Hazel Buchanan, Gabrielle S Le Provost, Zoe Donnellan, Ricardo J Carreira, Samantha J Paston, Luise U Weigand, Martina Canestraro, Joseph P Sanderson, Sophie Botta Gordon-Smith, Kate L Lowe, Karolina A Rygiel, Alex S Powlesland, Annelise Vuidepot, Namir J Hassan, Brian J Cameron, Bent K Jakobsen, Joseph Dukes
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205491 (2018)
Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the preclinical development of drugs failed to adequately p
Externí odkaz:
https://doaj.org/article/c3d7165394b5442098ed39f7073a5fbd
Autor:
Jacob Hurst, Namir J. Hassan, Giovanna Bossi, Caroline Boudousquie, Bent K. Jakobsen, Karolina A. Rygiel
Publikováno v:
Immunology
Summary The success of immune system‐based cancer therapies depends on a broad immune response engaging a range of effector cells and mechanisms. Immune mobilizing monoclonal T cell receptors (TCRs) against cancer (ImmTAC™ molecules: fusion prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bd64c00a8dda8adc96bda5f21412156
http://europepmc.org/articles/PMC5629433
http://europepmc.org/articles/PMC5629433
Autor:
Namir J. Hassan, A N Barclay, Sarah Hanrahan, Marion H. Brown, Nicholas G. Clarkson, M Bomb, Stephen J. Simmonds, M J Puklavec
Publikováno v:
Molecular and cellular biology. 39(7)
Deciphering the role of lymphocyte membrane proteins depends on dissecting the role of a protein in the steady state and on engagement with its ligand. We show that expression of CD6 in T cells limits their responsiveness but that engagement by the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8be5f9f4f0450731fe5a3ea58b820503
https://pubmed.ncbi.nlm.nih.gov/16914752
https://pubmed.ncbi.nlm.nih.gov/16914752
Autor:
Milos Aleksic, Joanne Oates, Peter Eamon Molloy, Annelise Vuidepot, Giovanna Bossi, Namir J. Hassan, Gemma Hancock, Tara Mahon, Hongbing Yang, Sandrine Buisson, Lucy Dorrell, Rebecca Ashfield, Samantha Paston, Zoë Wallace, Chun So, Bent K. Jakobsen
Publikováno v:
Molecular Therapy. 24(11):1913-1925
Persistence of human immunodeficiency virus (HIV) in a latent state in long-lived CD4+ T-cells is a major barrier to eradication. Latency-reversing agents that induce direct or immune-mediated cell death upon reactivation of HIV are a possible soluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e2a52d8aa742ee32d2c92c733527472
Autor:
Leonel Hernandez-Aya, Pippa Corrie, M Sznol, Richard D. Carvajal, Namir J. Hassan, Jeff Evans, Middleton, Omid Hamid, C Mulatero, Alexander N. Shoushtari, Cheryl McAlpine, David Krige, Neil Steven, Joseph J. Sacco, N Little, J. R. Infante, Marlana Orloff, CM Coughlin, Takami Sato, Paul Nathan, Sandip Pravin Patel, A-M Hulstine
Publikováno v:
Journal for ImmunoTherapy of Cancer. 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b1395e39cda9dfcc2a88c8230ebe71a
https://doi.org/10.1186/s40425-017-0289-3
https://doi.org/10.1186/s40425-017-0289-3
Publikováno v:
Cancer Immunology, Immunotherapy. 63:437-448
Antigen cross-presentation by dendritic cells (DCs) is thought to play a critical role in driving a polyclonal and durable T cell response against cancer. It follows, therefore, that the capacity of emerging immunotherapeutic agents to orchestrate tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4278c01bae1b8cfe7220e46565950a4
https://doi.org/10.1007/s00262-014-1525-z
https://doi.org/10.1007/s00262-014-1525-z
Autor:
Namir J. Hassan, Joseph Dukes, Andrew M.F. Johnson, Annelise Vuidepot, Jane Harper, Brian Cameron, Emma Baston, Peter Eamon Molloy, Giovanna Bossi, C. Coughlin, Nathaniel Liddy, Malkit Sami, Tara Mahon, Bent K. Jakobsen, A. Powesland, Samantha Paston, L. Holt
Publikováno v:
European Journal of Cancer. 92:S15-S16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6a278856cd8a8436e2450b561ad3e96
https://doi.org/10.1016/j.ejca.2018.01.039
https://doi.org/10.1016/j.ejca.2018.01.039
Autor:
Sandra Herrero-Gonzalez, Cheryl McAlpine, Sanjay R. Patel, Namir J. Hassan, William Shingler, Sarah Franklin, David Krige, Bent K. Jakobsen, Andrew D. Johnson, Debbie Parker, Christina M. Coughlin, Jacob Hurst
Publikováno v:
Cancer Research. 77:3655-3655
IMCgp100, a first in class immunotherapy, is a T cell redirecting bispecific biologic comprising an affinity enhanced T-cell receptor specific for gp100 and an anti-CD3 scFV. Phase I/IIa data has provided evidence of a favourable safety profile, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b602b3ca18364bbcfc57a9f13ac133b3
https://doi.org/10.1158/1538-7445.am2017-3655
https://doi.org/10.1158/1538-7445.am2017-3655
Autor:
Andrew D. Johnson, Namir J. Hassan, Lindsay Bawden, Christina M. Coughlin, David Krige, Sanjay R. Patel, Cheryl McAlpine, Bent K. Jakobsen, William Shingler, Debbie Parker, Sandra Herrero Gonzalez
Publikováno v:
Cancer Immunology Research. 5:A35-A35
IMCgp100, a first in class immunotherapy, is a T cell redirecting bispecific biologic comprising an affinity enhanced T-cell receptor specific for gp100 and an anti-CD3 scFV. Phase I/IIa data supported a favourable safety profile and durable response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19b168dfd3ce004f81e0ca61b9a26267
https://doi.org/10.1158/2326-6074.tumimm16-a35
https://doi.org/10.1158/2326-6074.tumimm16-a35
Autor:
Jessie Gavarret, Katherine Adams, Jane Harper, Bent K. Jakobsen, Yi Li, Frayne Bianchi, Emma Baston, Michael Kalos, Penio Todorov, Malkit Sami, Steve M. Dunn, Emma Gostick, Nikolai Lissin, David Price, Rebecca Dennis, Peter Eamon Molloy, Samantha Paston, Gabriela Plesa, Kristin Ladell, Giovanna Bossi, Namir J. Hassan, Deborah H. Sutton, Naomi Harwood, Annelise Vuidepot, Carl H. June, Nicholas J. Pumphrey, Nathaniel Liddy, Yvonne McGrath, Brian Cameron, Daniel Williams, Andrew K. Sewell, Tara Mahon, Rebecca Ashfield, Anna Lissina, Andrew M.F. Johnson
Publikováno v:
Nature Medicine. 18:980-987
T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a minority of patients with cancer. In the majority of these individuals, however, there is a failure of the specific T cell receptor (TCR)–mediated immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505ae55c5e09e496a47351e2c4c0a005
https://doi.org/10.1038/nm.2764
https://doi.org/10.1038/nm.2764